<li>abiraterone<p>cyclosporine increases levels of abiraterone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>aceclofenac<p>aceclofenac increases toxicity of cyclosporine by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis, increasing the risk of nephrotoxicity.</p></li><li>acemetacin<p>acemetacin increases toxicity of cyclosporine by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis, increasing the risk of nephrotoxicity.</p></li><li>acyclovir<p>acyclovir and cyclosporine both increase  nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely.</p></li><li>adefovir<p>adefovir and cyclosporine both increase  nephrotoxicity and/or ototoxicity. Use Caution/Monitor.</p></li><li>aliskiren<p>cyclosporine will increase the level or effect of aliskiren by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Avoid concurrent use. Coadministration of 200 mg and 600 mg cyclosporine, with 75 mg aliskiren resulted in an approximately 2.5-fold increase in Cmax and 5-fold increase in AUC of aliskiren<span><br><br></span>cyclosporine will increase the level or effect of aliskiren by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor. Avoid concurrent use. Coadministration of 200 mg and 600 mg cyclosporine, with 75 mg aliskiren resulted in an approximately 2.5-fold increase in Cmax and 5-fold increase in AUC of aliskiren</p></li><li>alitretinoin<p>cyclosporine will increase the level or effect of alitretinoin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>almotriptan<p>cyclosporine will increase the level or effect of almotriptan by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>alprazolam<p>cyclosporine will increase the level or effect of alprazolam by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>aluminum hydroxide<p>aluminum hydroxide decreases levels of cyclosporine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Separate by 2 hours.</p></li><li>ambrisentan<p>cyclosporine will increase the level or effect of ambrisentan by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. 2-fold increase in ambrisentan exposure; limit ambrisentan dose to 5 mg/day when coadministered with cyclosporine</p></li><li>amikacin<p>cyclosporine will increase the level or effect of amikacin by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>amiodarone<p>cyclosporine will increase the level or effect of amiodarone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>amiodarone will increase the level or effect of cyclosporine by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>amitriptyline<p>cyclosporine will increase the level or effect of amitriptyline by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>cyclosporine will increase the level or effect of amitriptyline by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>amlodipine<p>amlodipine increases levels of cyclosporine by unspecified interaction mechanism. Modify Therapy/Monitor Closely. A prospective study in renal transplant recipients averaged a 40% increase in cyclosporine trough levels.</p></li><li>amobarbital<p>amobarbital will decrease the level or effect of cyclosporine by  affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor.<span><br><br></span>amobarbital will decrease the level or effect of cyclosporine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>aprepitant<p>aprepitant will increase the level or effect of cyclosporine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>cyclosporine will increase the level or effect of aprepitant by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>aripiprazole<p>cyclosporine will increase the level or effect of aripiprazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>armodafinil<p>armodafinil will decrease the level or effect of cyclosporine by  affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor.<span><br><br></span>armodafinil will decrease the level or effect of cyclosporine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>artemether/lumefantrine<p>artemether/lumefantrine will decrease the level or effect of cyclosporine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>cyclosporine will increase the level or effect of artemether/lumefantrine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>aspirin/citric acid/sodium bicarbonate<p>aspirin/citric acid/sodium bicarbonate increases toxicity of cyclosporine by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis, increasing the risk of nephrotoxicity.</p></li><li>astragalus<p>cyclosporine increases and astragalus decreases immunosuppressive effects; risk of infection. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>atazanavir<p>atazanavir will increase the level or effect of cyclosporine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>avanafil<p>cyclosporine will increase the level or effect of avanafil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. CYP3A4 inhibitors may reduce avanafil clearance increasing systemic exposure to avanafil; increased levels may result in increased associated adverse events; the maximum recommended dose of STENDRA is 50 mg, not to exceed once every 24 hours for patients taking concomitant moderate CYP3A4 inhibitors</p></li><li>azithromycin<p>cyclosporine will increase the level or effect of azithromycin by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>bazedoxifene/conjugated estrogens<p>cyclosporine will increase the level or effect of bazedoxifene/conjugated estrogens by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>cyclosporine will increase the level or effect of bazedoxifene/conjugated estrogens by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>belatacept<p>belatacept and cyclosporine both increase  immunosuppressive effects; risk of infection. Use Caution/Monitor.<span><br><br></span>cyclosporine will decrease the level or effect of belatacept by  decreasing metabolism. Modify Therapy/Monitor Closely. Monitor for a need to adjust concomitant mycophenolate mofetil (MMF) dosage when patientâ€™s therapy is switched between cyclosporine and belatacept, </p></li><li>benazepril<p>benazepril and cyclosporine both increase  nephrotoxicity and/or ototoxicity. Use Caution/Monitor. May increase risk of acute renal failure.</p></li><li>bexarotene<p>cyclosporine will increase the level or effect of bexarotene by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>blinatumomab<p>blinatumomab increases levels of cyclosporine by decreasing metabolism. Modify Therapy/Monitor Closely. Treatment initiation causes transient release of cytokines that may suppress CYP450 enzymes; highest drug-drug interaction risk is during the first 9 days of the first cycle and the first 2 days of the 2nd cycle in patients who are receiving concomitant CYP450 substrates, particularly those with a narrow therapeutic index.</p></li><li>boceprevir<p>boceprevir increases levels of cyclosporine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Plasma concentrations of cyclosporine are expected to be increased significantly during coadministration with boceprevir. Close monitoring of immunosuppressant blood levels is recommended.</p></li><li>bortezomib<p>cyclosporine will increase the level or effect of bortezomib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>bosutinib<p>bosutinib increases levels of cyclosporine by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>brexpiprazole<p>cyclosporine will increase the level or effect of brexpiprazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Administer a quarter of brexpiprazole dose if coadministered with a moderate CYP3A4 inhibitor PLUS a strong/moderate CYP2D6 inhibitor.</p></li><li>brodalumab<p>brodalumab, cyclosporine. Other (see comment). Use Caution/Monitor. 
Comment: Formation of CYP450 enzymes can be altered by increased levels of certain cytokines during chronic inflammation; thus, brodalumab could normalize the formation of CYP450 enzymes. Upon initiation or discontinuation of brodalumab in patients who are receiving concomitant CYP450 substrates, particularly those with a narrow therapeutic index, consider monitoring for therapeutic effect.</p></li><li>bromocriptine<p>bromocriptine increases levels of cyclosporine by decreasing metabolism. Use Caution/Monitor.</p></li><li>budesonide<p>cyclosporine will increase the level or effect of budesonide by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>cyclosporine will increase the level or effect of budesonide by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>buprenorphine subdermal implant<p>cyclosporine will increase the level or effect of buprenorphine subdermal implant by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Monitor patients already on buprenorphine subdermal implant who require newly-initiated treatment with CYP3A4 inhibitors for signs and symptoms of overmedication. If the dose of the concomitant CYP3A4 inhibitor cannot be reduced or discontinued, implant removal may be necessary and the patient should then be treated with a buprenorphine dosage form that permits dose adjustments. If a CYP3A4 inhibitor is discontinued in a patient who has been stabilized on buprenorphine, monitor the patient for withdrawal.</p></li><li>bupropion<p>cyclosporine increases toxicity of bupropion by unspecified interaction mechanism. Use Caution/Monitor. May lower seizure threshold; keep bupropion dose as low as possible.</p></li><li>buspirone<p>cyclosporine will increase the level or effect of buspirone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>butabarbital<p>butabarbital will decrease the level or effect of cyclosporine by  affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor.<span><br><br></span>butabarbital will decrease the level or effect of cyclosporine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>butalbital<p>butalbital will decrease the level or effect of cyclosporine by  affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor.<span><br><br></span>butalbital will decrease the level or effect of cyclosporine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>cabazitaxel<p>cyclosporine will increase the level or effect of cabazitaxel by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Caution should be exercised with concomitant use of moderate CYP3A4 inhibitors.</p></li><li>cabozantinib<p>cyclosporine will increase the level or effect of cabozantinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>calcium carbonate<p>calcium carbonate decreases levels of cyclosporine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Separate by 2 hours.</p></li><li>canagliflozin<p>cyclosporine and canagliflozin both increase  serum potassium. Use Caution/Monitor.</p></li><li>capreomycin<p>capreomycin and cyclosporine both increase  nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely.</p></li><li>captopril<p>captopril, cyclosporine.
Either increases toxicity of the other by Mechanism: unspecified interaction mechanism. Use Caution/Monitor. Risk of acute renal failure.</p></li><li>carbamazepine<p>carbamazepine will decrease the level or effect of cyclosporine by  affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor.<span><br><br></span>cyclosporine will increase the level or effect of carbamazepine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>carboplatin<p>carboplatin and cyclosporine both increase  nephrotoxicity and/or ototoxicity. Use Caution/Monitor.</p></li><li>celecoxib<p>celecoxib, cyclosporine.
Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely.</p></li><li>cephaloridine<p>cephaloridine and cyclosporine both increase  nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely.</p></li><li>ceritinib<p>cyclosporine increases levels of ceritinib by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>chloroquine<p>chloroquine increases levels of cyclosporine by decreasing metabolism. Use Caution/Monitor.</p></li><li>cholera vaccine<p>cyclosporine decreases effects of cholera vaccine by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Immunosuppressive therapies, including irradiation, antimetabolites, alkylating agents, cytotoxic drugs and corticosteroids (used in greater than physiologic doses), may reduce the immune response to cholera vaccine.</p></li><li>cholic acid<p>cyclosporine increases toxicity of cholic acid by decreasing elimination. Modify Therapy/Monitor Closely. Avoid concomitant use of inhibitors of the bile salt efflux pump (BSEP). May exacerbate accumulation of conjugated bile salts in the liver and result in clinical symptoms. If concomitant use is necessary, monitor serum transaminases and bilirubin.</p></li><li>cigarette smoking<p>cigarette smoking will decrease the level or effect of cyclosporine by  affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor.</p></li><li>cilostazol<p>cyclosporine will increase the level or effect of cilostazol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>cimetidine<p>cimetidine will increase the level or effect of cyclosporine by  affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor.</p></li><li>cinacalcet<p>cyclosporine will increase the level or effect of cinacalcet by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>ciprofloxacin<p>ciprofloxacin will increase the level or effect of cyclosporine by  affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor. Ciprofloxacin may cause transient elevations in serum creatinine in patients receiving concomitant cyclosporine and ciprofloxacin therapy. Ciprofloxacin may enhance the nephrotoxic effects of cyclosporine during concurrent use.</p></li><li>cisplatin<p>cisplatin and cyclosporine both increase  nephrotoxicity and/or ototoxicity. Use Caution/Monitor.</p></li><li>clarithromycin<p>clarithromycin will increase the level or effect of cyclosporine by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>clobetasone<p>cyclosporine will increase the level or effect of clobetasone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>cyclosporine will increase the level or effect of clobetasone by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>clomipramine<p>cyclosporine will increase the level or effect of clomipramine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>clopidogrel<p>cyclosporine will decrease the level or effect of clopidogrel by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Inhibition of CYP3A4 will reduce clopidogrel bioactivation</p></li><li>clotrimazole<p>clotrimazole will decrease the level or effect of cyclosporine by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>clozapine<p>cyclosporine will increase the level or effect of clozapine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>cobicistat<p>cobicistat will increase the level or effect of cyclosporine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely.</p></li><li>colchicine<p>cyclosporine will increase the level or effect of colchicine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Coadministration significantly increases plasma levels and toxic effects of colchicine (eg, myopathy, neuropathy), especially in presence of renal impairment; prescribing information recommends reducing colchicine dose<span><br><br></span>cyclosporine will increase the level or effect of colchicine by  P-glycoprotein (MDR1) efflux transporter. Modify Therapy/Monitor Closely. Coadministration significantly increases plasma levels and toxic effects of colchicine (eg, myopathy, neuropathy), especially in presence of renal impairment; prescribing information recommends reducing colchicine dose<span><br><br></span>colchicine increases effects of cyclosporine by pharmacodynamic synergism. Use Caution/Monitor.</p></li><li>colesevelam<p>colesevelam decreases levels of cyclosporine by drug binding in GI tract. Use Caution/Monitor. Concomitant administration decreases cyclosporine absorption; however, absorption is not reduced when cyclosporine is administered 4 hr before colesevelam.</p></li><li>colistin<p>colistin and cyclosporine both increase  nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely.</p></li><li>conivaptan<p>conivaptan will increase the level or effect of cyclosporine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>cyclosporine will increase the level or effect of conivaptan by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>conjugated estrogens<p>cyclosporine will increase the level or effect of conjugated estrogens by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>cyclosporine will increase the level or effect of conjugated estrogens by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.<span><br><br></span>cyclosporine will increase the level or effect of conjugated estrogens by  Other (see comment). Use Caution/Monitor. may increase plasma concentrations of organic anion transporter protein substrates</p></li><li>conjugated estrogens, vaginal<p>cyclosporine will increase the level or effect of conjugated estrogens, vaginal by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>cyclosporine will increase the level or effect of conjugated estrogens, vaginal by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>cortisone<p>cyclosporine will increase the level or effect of cortisone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>cyclosporine will increase the level or effect of cortisone by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>crizotinib<p>crizotinib increases levels of cyclosporine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Coadministration of crizotinib with CYP3A substrates with narrow therapeutic indices should be avoided.<span><br><br></span>cyclosporine increases levels of crizotinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Caution should be exercised with concomitant use of moderate CYP3A inhibitors. .</p></li><li>crofelemer<p>crofelemer increases levels of cyclosporine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Crofelemer has the potential to inhibit CYP3A4 at concentrations expected in the gut; unlikely to inhibit systemically because minimally absorbed.</p></li><li>dabigatran<p>cyclosporine will increase the level or effect of dabigatran by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor. Atrial fibrillation: Avoid coadministering dabigatran with P-gp inhibitors if CrCl &lt;30 mL/min.  DVT/PE treatment: Avoid coadministering dabigatran with P-gp inhibitors if CrCl &lt;50 mL/min</p></li><li>dabrafenib<p>dabrafenib will decrease the level or effect of cyclosporine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely.</p></li><li>daclatasvir<p>daclatasvir will increase the level or effect of cyclosporine by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>darifenacin<p>cyclosporine will increase the level or effect of darifenacin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>darunavir<p>cyclosporine will increase the level or effect of darunavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>darunavir will increase the level or effect of cyclosporine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>dasatinib<p>cyclosporine will increase the level or effect of dasatinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>dasatinib will increase the level or effect of cyclosporine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>daunorubicin<p>cyclosporine will increase the level or effect of daunorubicin by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>daunorubicin liposomal<p>cyclosporine will increase the level or effect of daunorubicin liposomal by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>deferasirox<p>deferasirox will decrease the level or effect of cyclosporine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>deflazacort<p>cyclosporine will increase the level or effect of deflazacort by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Decrease deflazacort dose to one-third of the recommended dose if coadministered with moderate or strong CYP3A4 inhibitors.<span><br><br></span>cyclosporine will increase the level or effect of deflazacort by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>delavirdine<p>delavirdine will increase the level or effect of cyclosporine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>denosumab<p>cyclosporine, denosumab. Other (see comment). Use Caution/Monitor. 
Comment: Caution should be taken in patients on concomitant immunosuppressants or with impaired immune systems because of increased risk for serious infections.</p></li><li>desipramine<p>cyclosporine will increase the level or effect of desipramine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>dexamethasone<p>cyclosporine will increase the level or effect of dexamethasone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>cyclosporine will increase the level or effect of dexamethasone by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>dexlansoprazole<p>dexlansoprazole, cyclosporine.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: When used for prolonged periods of time PPIs may cause hypomagnesemia and the risk is further increased when used concomitantly with drugs that also have the same effects.<span><br><br></span>cyclosporine, dexlansoprazole.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: When used for prolonged periods of time PPIs may cause hypomagnesemia and the risk is further increased when used concomitantly with drugs that also have the same effects.</p></li><li>dhea, herbal<p>dhea, herbal will increase the level or effect of cyclosporine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>diazepam<p>cyclosporine will increase the level or effect of diazepam by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>dichlorphenamide<p>dichlorphenamide, cyclosporine.
Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Both drugs can cause metabolic acidosis.</p></li><li>diclofenac<p>diclofenac, cyclosporine.
Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Potential for dangerous interaction. Use with caution and monitor closely.</p></li><li>diflunisal<p>diflunisal, cyclosporine.
Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Potential for dangerous interaction. Use with caution and monitor closely.</p></li><li>digoxin<p>cyclosporine will increase the level or effect of digoxin by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>diltiazem<p>diltiazem will increase the level or effect of cyclosporine by  affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor.<span><br><br></span>cyclosporine will increase the level or effect of diltiazem by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>diltiazem will increase the level or effect of cyclosporine by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor. If given concomitantly, monitor circulating cyclosporine levels and adjust cyclosporine dosage as necessary. Also monitor patients for increased cyclosporine toxicity (renal dysfunction, cholestasis, paresthesias).<span><br><br></span>diltiazem increases levels of cyclosporine by unknown mechanism. Use Caution/Monitor.</p></li><li>docetaxel<p>cyclosporine will increase the level or effect of docetaxel by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>doxorubicin<p>cyclosporine will increase the level or effect of doxorubicin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>cyclosporine will increase the level or effect of doxorubicin by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.<span><br><br></span>cyclosporine increases levels of doxorubicin by decreasing renal clearance. Use Caution/Monitor.</p></li><li>doxorubicin liposomal<p>cyclosporine will increase the level or effect of doxorubicin liposomal by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>cyclosporine will increase the level or effect of doxorubicin liposomal by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.<span><br><br></span>cyclosporine increases levels of doxorubicin liposomal by decreasing renal clearance. Use Caution/Monitor.</p></li><li>dronabinol<p>dronabinol increases levels of cyclosporine by plasma protein binding competition. Modify Therapy/Monitor Closely. Dronabinol is highly bound to plasma proteins and may displace and increase the free fraction of other concomitantly administered highly protein-bound drugs. This has not been confirmed in vivo. Caution with narrow therapeutic index drugs that are highly protein bound when initiating or increasing the dose of dronabinol.</p></li><li>dronedarone<p>dronedarone will increase the level or effect of cyclosporine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>dronedarone will increase the level or effect of cyclosporine by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor. Risk of QTc prolongation and cyclosporine toxicity.</p></li><li>dulaglutide<p>dulaglutide, cyclosporine. Other (see comment). Use Caution/Monitor. 
Comment: Dulaglutide slows gastric emptying and may impact absorption of concomitantly administered oral medications; be particularly cautious when coadministered with drugs that have a narrow therapeutic index.</p></li><li>dupilumab<p>dupilumab, cyclosporine. Other (see comment). Use Caution/Monitor. 
Comment: Formation of CYP450 enzymes can be altered by increased levels of certain cytokines during chronic inflammation; thus, dupilumab could normalize the formation of CYP450 enzymes. Upon initiation or discontinuation of dupilumab in patients who are receiving concomitant CYP450 substrates, particularly those with a narrow therapeutic index, consider monitoring for therapeutic effect.</p></li><li>dyphylline<p>cyclosporine will increase the level or effect of dyphylline by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>echinacea<p>cyclosporine increases and echinacea decreases immunosuppressive effects; risk of infection. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>efavirenz<p>efavirenz will decrease the level or effect of cyclosporine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>eletriptan<p>cyclosporine will increase the level or effect of eletriptan by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>eliglustat<p>eliglustat increases levels of cyclosporine by P-glycoprotein (MDR1) efflux transporter. Modify Therapy/Monitor Closely. Monitor therapeutic drug concentrations, as indicated, or consider reducing the dosage of the P-gp substrate and titrate to clinical effect.</p></li><li>eluxadoline<p>eluxadoline increases levels of cyclosporine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Caution when CYP3A substrates that have a narrow therapeutic index are coadministered with eluxadoline.</p></li><li>elvitegravir/cobicistat/emtricitabine/tenofovir df<p>elvitegravir/cobicistat/emtricitabine/tenofovir df increases levels of cyclosporine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Cobicistat is a CYP3A4 inhibitor; contraindicated with CYP3A4 substrates for which elevated plasma concentrations are associated with serious and/or life-threatening events.<span><br><br></span>cyclosporine and elvitegravir/cobicistat/emtricitabine/tenofovir df both increase  nephrotoxicity and/or ototoxicity. Use Caution/Monitor.</p></li><li>enalapril<p>enalapril increases levels of cyclosporine by unknown mechanism. Use Caution/Monitor.<span><br><br></span>enalapril, cyclosporine. Mechanism: unspecified interaction mechanism. Use Caution/Monitor. Risk of acute renal failure.</p></li><li>erlotinib<p>cyclosporine will increase the level or effect of erlotinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>cyclosporine will increase the level or effect of erlotinib by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>erythromycin base<p>erythromycin base will increase the level or effect of cyclosporine by  affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor.<span><br><br></span>erythromycin base will increase the level or effect of cyclosporine by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.<span><br><br></span>cyclosporine will increase the level or effect of erythromycin base by  Other (see comment). Use Caution/Monitor. may increase plasma concentrations of organic anion transporter protein substrates</p></li><li>erythromycin ethylsuccinate<p>erythromycin ethylsuccinate will increase the level or effect of cyclosporine by  affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor.<span><br><br></span>erythromycin ethylsuccinate will increase the level or effect of cyclosporine by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.<span><br><br></span>cyclosporine will increase the level or effect of erythromycin ethylsuccinate by  Other (see comment). Use Caution/Monitor. may increase plasma concentrations of organic anion transporter protein substrates</p></li><li>erythromycin lactobionate<p>erythromycin lactobionate will increase the level or effect of cyclosporine by  affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor.<span><br><br></span>erythromycin lactobionate will increase the level or effect of cyclosporine by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.<span><br><br></span>cyclosporine will increase the level or effect of erythromycin lactobionate by  Other (see comment). Use Caution/Monitor. may increase plasma concentrations of organic anion transporter protein substrates</p></li><li>erythromycin stearate<p>erythromycin stearate will increase the level or effect of cyclosporine by  affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor.<span><br><br></span>erythromycin stearate will increase the level or effect of cyclosporine by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.<span><br><br></span>cyclosporine will increase the level or effect of erythromycin stearate by  Other (see comment). Use Caution/Monitor. may increase plasma concentrations of organic anion transporter protein substrates</p></li><li>eslicarbazepine acetate<p>eslicarbazepine acetate will decrease the level or effect of cyclosporine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>esomeprazole<p>esomeprazole, cyclosporine.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: When used for prolonged periods of time PPIs may cause hypomagnesemia and the risk is further increased when used concomitantly with drugs that also have the same effects.</p></li><li>estradiol<p>cyclosporine will increase the level or effect of estradiol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>cyclosporine will increase the level or effect of estradiol by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>estrogens conjugated synthetic<p>cyclosporine will increase the level or effect of estrogens conjugated synthetic by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>cyclosporine will increase the level or effect of estrogens conjugated synthetic by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>estrogens esterified<p>cyclosporine will increase the level or effect of estrogens esterified by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>estropipate<p>cyclosporine will increase the level or effect of estropipate by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>cyclosporine will increase the level or effect of estropipate by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>ethanol<p>ethanol decreases levels of cyclosporine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Interaction only studied with red wine. Neoral may be less affected than Sandimmune.</p></li><li>ethinylestradiol<p>ethinylestradiol increases levels of cyclosporine by unknown mechanism. Use Caution/Monitor.</p></li><li>ethotoin<p>ethotoin will decrease the level or effect of cyclosporine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>ethotoin will decrease the level or effect of cyclosporine by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>etodolac<p>etodolac, cyclosporine.
Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Potential for dangerous interaction. Use with caution and monitor closely.</p></li><li>etonogestrel<p>cyclosporine will increase the level or effect of etonogestrel by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>etoposide<p>cyclosporine will increase the level or effect of etoposide by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.<span><br><br></span>cyclosporine increases levels of etoposide by decreasing elimination. Use Caution/Monitor. Interaction seen with high dose cyclosporine. Serum etoposide concentrations may be elevated, resulting in increased toxicity. Monitor complete blood cell count and adjust the dose of etoposide as needed.</p></li><li>etoricoxib<p>etoricoxib increases toxicity of cyclosporine by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis, increasing the risk of nephrotoxicity.</p></li><li>etravirine<p>cyclosporine will increase the level or effect of etravirine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>etravirine will decrease the level or effect of cyclosporine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>eucalyptus<p>eucalyptus will decrease the level or effect of cyclosporine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>famotidine<p>famotidine will increase the level or effect of cyclosporine by  unknown mechanism. Modify Therapy/Monitor Closely.</p></li><li>felodipine<p>cyclosporine will increase the level or effect of felodipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>felodipine will increase the level or effect of cyclosporine by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>fenbufen<p>fenbufen increases toxicity of cyclosporine by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis, increasing the risk of nephrotoxicity.</p></li><li>fenoprofen<p>fenoprofen, cyclosporine.
Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Potential for dangerous interaction. Use with caution and monitor closely.</p></li><li>fesoterodine<p>cyclosporine will increase the level or effect of fesoterodine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>fexofenadine<p>cyclosporine will increase the level or effect of fexofenadine by  Other (see comment). Use Caution/Monitor. may increase plasma concentrations of organic anion transporter protein substrates</p></li><li>fingolimod<p>cyclosporine increases effects of fingolimod by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Concomitant therapy is expected to increase the risk of immunosuppression. Use caution when switching patients from long-acting therapies with immune effects. .</p></li><li>flibanserin<p>flibanserin increases levels of cyclosporine by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor. Increase monitoring of concentrations of drugs transported by P-gp that have a narrow therapeutic index if coadministered with flibanserin.</p></li><li>fluconazole<p>fluconazole will increase the level or effect of cyclosporine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>fludrocortisone<p>cyclosporine will increase the level or effect of fludrocortisone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>cyclosporine will increase the level or effect of fludrocortisone by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>flurbiprofen<p>flurbiprofen, cyclosporine.
Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely.</p></li><li>fluvoxamine<p>fluvoxamine will increase the level or effect of cyclosporine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely.</p></li><li>fosamprenavir<p>cyclosporine will increase the level or effect of fosamprenavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>fosamprenavir will increase the level or effect of cyclosporine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>foscarnet<p>cyclosporine and foscarnet both increase  nephrotoxicity and/or ototoxicity. Use Caution/Monitor.</p></li><li>fosinopril<p>fosinopril, cyclosporine. Mechanism: unspecified interaction mechanism. Use Caution/Monitor. Risk of acute renal failure.</p></li><li>fosphenytoin<p>fosphenytoin will decrease the level or effect of cyclosporine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>fosphenytoin will decrease the level or effect of cyclosporine by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>furosemide<p>cyclosporine increases toxicity of furosemide by Other (see comment). Use Caution/Monitor. 
Comment: Concomitant use of cyclosporine and furosemide is associated with increased risk of gouty arthritis secondary to furosemide-induced hyperurecemia and cyclosporine impairment of renal urate excretion.</p></li><li>gentamicin<p>cyclosporine will increase the level or effect of gentamicin by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.<span><br><br></span>cyclosporine and gentamicin both increase  nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely.</p></li><li>glycerol phenylbutyrate<p>glycerol phenylbutyrate will decrease the level or effect of cyclosporine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Glycerol phenylbutyrate is a weak inducer of CYP3A4. Monitor for decreased efficacy of CYP3A4 substrates that have a narrow therapeutic index.</p></li><li>grapefruit<p>grapefruit will increase the level or effect of cyclosporine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>griseofulvin<p>griseofulvin will decrease the level or effect of cyclosporine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>guanfacine<p>cyclosporine will increase the level or effect of guanfacine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Strong or moderate CYP3A4 inhibitors significantly increase guanfacine plasma concentrations. FDA-approved labeling for extended-release (ER) guanfacine recommends that, if coadministered, the guanfacine dosage should be decreased to half of the recommended dose. Specific recommendations for immediate-release (IR) guanfacine are not available. </p></li><li>hexobarbital<p>hexobarbital will decrease the level or effect of cyclosporine by  affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor.<span><br><br></span>hexobarbital will decrease the level or effect of cyclosporine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>hydrochlorothiazide<p>cyclosporine increases toxicity of hydrochlorothiazide by unspecified interaction mechanism. Use Caution/Monitor. Increases risk of hyperuricemia and gout-type complications.</p></li><li>hydrocortisone<p>cyclosporine will increase the level or effect of hydrocortisone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>cyclosporine will increase the level or effect of hydrocortisone by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>hydroxyprogesterone caproate<p>cyclosporine will increase the level or effect of hydroxyprogesterone caproate by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>ibuprofen<p>ibuprofen, cyclosporine.
Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Potential for dangerous interaction. Use with caution and monitor closely.</p></li><li>iloperidone<p>cyclosporine will increase the level or effect of iloperidone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>iloperidone increases levels of cyclosporine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Iloperidone is a time-dependent CYP3A inhibitor and may lead to increased plasma levels of drugs predominantly eliminated by CYP3A4.</p></li><li>imatinib<p>cyclosporine will increase the level or effect of imatinib by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.<span><br><br></span>imatinib increases levels of cyclosporine by decreasing metabolism. Use Caution/Monitor.<span><br><br></span>cyclosporine will increase the level or effect of imatinib by  Other (see comment). Use Caution/Monitor. may increase plasma concentrations of organic anion transporter protein substrates</p></li><li>imidapril<p>imidapril, cyclosporine. Mechanism: unspecified interaction mechanism. Use Caution/Monitor. Risk of acute renal failure.</p></li><li>imipramine<p>cyclosporine will increase the level or effect of imipramine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>indinavir<p>cyclosporine will increase the level or effect of indinavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>cyclosporine will increase the level or effect of indinavir by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>indomethacin<p>indomethacin, cyclosporine.
Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely.</p></li><li>influenza virus vaccine quadrivalent, recombinant<p>cyclosporine decreases effects of influenza virus vaccine quadrivalent, recombinant by pharmacodynamic antagonism. Use Caution/Monitor. Immune response to vaccine may be decreased in immunocompromised individuals.</p></li><li>influenza virus vaccine trivalent, recombinant<p>cyclosporine decreases effects of influenza virus vaccine trivalent, recombinant by pharmacodynamic antagonism. Use Caution/Monitor. Immune response to vaccine may be decreased in immunocompromised individuals.</p></li><li>irinotecan<p>cyclosporine will increase the level or effect of irinotecan by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.<span><br><br></span>cyclosporine will increase the level or effect of irinotecan by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>irinotecan liposomal<p>cyclosporine will increase the level or effect of irinotecan liposomal by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>cyclosporine will increase the level or effect of irinotecan liposomal by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>isoniazid<p>isoniazid will increase the level or effect of cyclosporine by  affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor.</p></li><li>itraconazole<p>cyclosporine will increase the level or effect of itraconazole by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>ivermectin<p>cyclosporine will increase the level or effect of ivermectin by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>ixabepilone<p>cyclosporine will increase the level or effect of ixabepilone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>ixekizumab<p>ixekizumab, cyclosporine. Other (see comment). Use Caution/Monitor. 
Comment: Formation of CYP450 enzymes can be altered by increased levels of certain cytokines during chronic inflammation; thus, ixekizumab could normalize the formation of CYP450 enzymes. Upon initiation or discontinuation of ixekizumab in patients who are receiving concomitant CYP450 substrates, particularly those with a narrow therapeutic index, consider monitoring for therapeutic effect.</p></li><li>kanamycin<p>cyclosporine will increase the level or effect of kanamycin by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.<span><br><br></span>cyclosporine and kanamycin both increase  nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely.</p></li><li>ketoconazole<p>ketoconazole will increase the level or effect of cyclosporine by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>ketoprofen<p>ketoprofen, cyclosporine.
Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely.</p></li><li>ketorolac<p>ketorolac, cyclosporine.
Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely.</p></li><li>lacidipine<p>cyclosporine will increase the level or effect of lacidipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>lanreotide<p>lanreotide decreases levels of cyclosporine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.</p></li><li>lansoprazole<p>cyclosporine, lansoprazole.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: When used for prolonged periods of time PPIs may cause hypomagnesemia and the risk is further increased when used concomitantly with drugs that also have the same effects.<span><br><br></span>lansoprazole, cyclosporine.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: When used for prolonged periods of time PPIs may cause hypomagnesemia and the risk is further increased when used concomitantly with drugs that also have the same effects.</p></li><li>lapatinib<p>cyclosporine will increase the level or effect of lapatinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>lapatinib will increase the level or effect of cyclosporine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>cyclosporine will increase the level or effect of lapatinib by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>lercanidipine<p>cyclosporine will increase the level or effect of lercanidipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>cyclosporine, lercanidipine.
Either increases levels of the other by decreasing metabolism. Use Caution/Monitor.</p></li><li>levobupivacaine<p>cyclosporine will increase the level or effect of levobupivacaine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>levothyroxine<p>cyclosporine will increase the level or effect of levothyroxine by  Other (see comment). Use Caution/Monitor. may increase plasma concentrations of OATP substrates</p></li><li>lisinopril<p>lisinopril, cyclosporine. Mechanism: unspecified interaction mechanism. Use Caution/Monitor. Risk of acute renal failure.</p></li><li>lomitapide<p>lomitapide increases levels of cyclosporine by P-glycoprotein (MDR1) efflux transporter. Modify Therapy/Monitor Closely. Consider reducing dose when used concomitantly with lomitapide.</p></li><li>loperamide<p>cyclosporine will increase the level or effect of loperamide by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>lopinavir<p>cyclosporine will increase the level or effect of lopinavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>loratadine<p>cyclosporine will increase the level or effect of loratadine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>loratadine will increase the level or effect of cyclosporine by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>lornoxicam<p>lornoxicam increases toxicity of cyclosporine by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis, increasing the risk of nephrotoxicity.</p></li><li>lumefantrine<p>cyclosporine will increase the level or effect of lumefantrine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>lumefantrine will decrease the level or effect of cyclosporine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>maitake<p>cyclosporine increases and maitake decreases immunosuppressive effects; risk of infection. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>maraviroc<p>cyclosporine will increase the level or effect of maraviroc by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>cyclosporine will increase the level or effect of maraviroc by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>marijuana<p>marijuana will increase the level or effect of cyclosporine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>meclofenamate<p>meclofenamate, cyclosporine.
Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Potential for dangerous interaction. Use with caution and monitor closely.<span><br><br></span>meclofenamate increases toxicity of cyclosporine by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis, increasing the risk of nephrotoxicity.</p></li><li>mefenamic acid<p>mefenamic acid, cyclosporine.
Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely.</p></li><li>mefloquine<p>cyclosporine will increase the level or effect of mefloquine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>meloxicam<p>meloxicam, cyclosporine.
Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely.</p></li><li>melphalan<p>melphalan increases toxicity of cyclosporine by unknown mechanism. Use Caution/Monitor. Increased risk of nephrotoxicity.</p></li><li>meningococcal group b vaccine<p>cyclosporine decreases effects of meningococcal group b vaccine by pharmacodynamic antagonism. Use Caution/Monitor. Individuals with altered immunocompetence may have reduced immune responses to the vaccine.</p></li><li>mephobarbital<p>mephobarbital will decrease the level or effect of cyclosporine by  affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor.<span><br><br></span>mephobarbital will decrease the level or effect of cyclosporine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>mercaptopurine<p>cyclosporine and mercaptopurine both increase  immunosuppressive effects; risk of infection. Use Caution/Monitor.</p></li><li>mestranol<p>cyclosporine will increase the level or effect of mestranol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>cyclosporine will increase the level or effect of mestranol by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>methadone<p>cyclosporine will increase the level or effect of methadone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>methotrexate<p>cyclosporine and methotrexate both increase  nephrotoxicity and/or ototoxicity. Use Caution/Monitor. Either drug may increase the concentration of the other. Monitoring of methotrexate and cyclosporine concentrations during concurrent cyclosporine therapy is recommended.<span><br><br></span>cyclosporine, methotrexate. Other (see comment). Use Caution/Monitor. 
Comment: Methotrexate levels were increased ~30% and 7-hydroxy methotrexate (metabolite) levels were decreased ~80%.</p></li><li>methoxyflurane<p>cyclosporine and methoxyflurane both increase  nephrotoxicity and/or ototoxicity. Use Caution/Monitor.</p></li><li>methylprednisolone<p>cyclosporine will increase the level or effect of methylprednisolone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Seizures reported when high dose methylprednisolone coadministered with cyclosporine<span><br><br></span>cyclosporine will increase the level or effect of methylprednisolone by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor. Seizures reported when high dose methylprednisolone coadministered with cyclosporine</p></li><li>methyltestosterone<p>methyltestosterone increases effects of cyclosporine by decreasing metabolism. Use Caution/Monitor.</p></li><li>metoclopramide<p>metoclopramide increases levels of cyclosporine by enhancing GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.</p></li><li>metronidazole<p>metronidazole will increase the level or effect of cyclosporine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>mexiletine<p>mexiletine will increase the level or effect of cyclosporine by  affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor.</p></li><li>mibefradil<p>mibefradil will increase the level or effect of cyclosporine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>miconazole vaginal<p>miconazole vaginal will increase the level or effect of cyclosporine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>midazolam<p>cyclosporine will increase the level or effect of midazolam by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>midazolam will decrease the level or effect of cyclosporine by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>mitotane<p>mitotane decreases levels of cyclosporine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Mitotane is a strong inducer of cytochrome P-4503A4; monitor when coadministered with CYP3A4 substrates for possible dosage adjustments.</p></li><li>mitoxantrone<p>cyclosporine increases toxicity of mitoxantrone by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor. Therapeutic and toxic effects of mitoxantrone may be increased by cyclosporine. Close clinical and laboratory monitoring are indicated.</p></li><li>mizolastine<p>cyclosporine increases levels of mizolastine by decreasing metabolism. Use Caution/Monitor.</p></li><li>modafinil<p>modafinil will decrease the level or effect of cyclosporine by  affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor.<span><br><br></span>modafinil will decrease the level or effect of cyclosporine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>moexipril<p>moexipril, cyclosporine. Mechanism: unspecified interaction mechanism. Use Caution/Monitor. Risk of acute renal failure.</p></li><li>mycophenolate<p>cyclosporine will increase the level or effect of mycophenolate by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>nabumetone<p>nabumetone, cyclosporine.
Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely.</p></li><li>nafcillin<p>nafcillin will decrease the level or effect of cyclosporine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>naproxen<p>naproxen, cyclosporine.
Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely.</p></li><li>nefazodone<p>nefazodone will decrease the level or effect of cyclosporine by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>nelfinavir<p>cyclosporine will increase the level or effect of nelfinavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>cyclosporine will increase the level or effect of nelfinavir by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>neomycin po<p>cyclosporine will increase the level or effect of neomycin po by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>netilmicin<p>cyclosporine will increase the level or effect of netilmicin by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.<span><br><br></span>cyclosporine and netilmicin both increase  nephrotoxicity and/or ototoxicity. Use Caution/Monitor.</p></li><li>nevirapine<p>nevirapine will decrease the level or effect of cyclosporine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>nicardipine<p>cyclosporine will increase the level or effect of nicardipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>nicardipine will increase the level or effect of cyclosporine by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.<span><br><br></span>nicardipine increases levels of cyclosporine by decreasing metabolism. Use Caution/Monitor.<span><br><br></span>nicardipine increases levels of cyclosporine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>nifedipine<p>nifedipine will increase the level or effect of cyclosporine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>nifedipine will decrease the level or effect of cyclosporine by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>nilotinib<p>cyclosporine will increase the level or effect of nilotinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>nilotinib will increase the level or effect of cyclosporine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>cyclosporine will increase the level or effect of nilotinib by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>nintedanib<p>cyclosporine increases levels of nintedanib by P-glycoprotein (MDR1) efflux transporter. Modify Therapy/Monitor Closely. If nintedanib adverse effects occur, management may require interruption, dose reduction, or discontinuation of therapy.</p></li><li>nisoldipine<p>cyclosporine will increase the level or effect of nisoldipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>nizatidine<p>nizatidine will increase the level or effect of cyclosporine by  unknown mechanism. Modify Therapy/Monitor Closely.</p></li><li>norfloxacin<p>norfloxacin will increase the level or effect of cyclosporine by  affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor.</p></li><li>nortriptyline<p>cyclosporine will increase the level or effect of nortriptyline by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>ocrelizumab<p>cyclosporine and ocrelizumab both increase  immunosuppressive effects; risk of infection. Use Caution/Monitor. Coadministration of ocrelizumab with immunosuppessants is expected to increase the risk of immunosuppression.</p></li><li>octreotide<p>octreotide decreases levels of cyclosporine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.</p></li><li>octreotide (antidote)<p>octreotide (antidote) decreases levels of cyclosporine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.</p></li><li>ombitasvir/paritaprevir/ritonavir<p>ombitasvir/paritaprevir/ritonavir will increase the level or effect of cyclosporine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. When initiating therapy with Technivie, reduce cyclosporine dose to 1/5th of the patientâ€™s current cyclosporine dose; measure cyclosporine blood concentrations to determine subsequent dose modifications; upon completion of Technivie, the appropriate time to resume pre-Technivie dose of cyclosporine should be guided by assessment of cyclosporine blood concentrations; also monitor renal function and cyclosporine-related side effects when coadministered.<span><br><br></span>ombitasvir/paritaprevir/ritonavir will increase the level or effect of cyclosporine by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor. Paritaprevir and ritonavir inhibit P-gp. Caution if coadministered with P-gp substrates.</p></li><li>ombitasvir/paritaprevir/ritonavir &amp; dasabuvir<p>ombitasvir/paritaprevir/ritonavir &amp; dasabuvir will increase the level or effect of cyclosporine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. When initiating therapy with Viekira Pak, reduce cyclosporine dose to 1/5th of the patientâ€™s current cyclosporine dose; measure cyclosporine blood concentrations to determine subsequent dose modifications; upon completion of Viekira Pak, the appropriate time to resume pre-Viekira Pak dose of cyclosporine should be guided by assessment of cyclosporine blood concentrations;  also monitor renal function and cyclosporine-related side effects when coadministered<span><br><br></span>cyclosporine will increase the level or effect of ombitasvir/paritaprevir/ritonavir &amp; dasabuvir by  Other (see comment). Use Caution/Monitor. may increase plasma concentrations of OATP substrates</p></li><li>omeprazole<p>omeprazole will decrease the level or effect of cyclosporine by  affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor.<span><br><br></span>omeprazole, cyclosporine.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: When used for prolonged periods of time PPIs may cause hypomagnesemia and the risk is further increased when used concomitantly with drugs that also have the same effects.</p></li><li>oritavancin<p>oritavancin will decrease the level or effect of cyclosporine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Oritavancin is a weak CYP3A4 inducer; caution if coadministered with CYP3A4 substrates that have a narrow therapeutic index</p></li><li>orlistat<p>orlistat decreases levels of cyclosporine by inhibition of GI absorption. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Administer cyclosporine 3 hours after orlistat .</p></li><li>osimertinib<p>osimertinib, cyclosporine. affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Osimertinib is a competitive inhibitor and inducer of CYP3A. Monitor sensitive CYP3A substrates for alterations in serum levels or efficacy/toxicity.</p></li><li>oxaliplatin<p>cyclosporine and oxaliplatin both increase  nephrotoxicity and/or ototoxicity. Use Caution/Monitor.</p></li><li>oxaprozin<p>oxaprozin, cyclosporine.
Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely.</p></li><li>oxcarbazepine<p>oxcarbazepine will decrease the level or effect of cyclosporine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>oxiconazole<p>oxiconazole will increase the level or effect of cyclosporine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>paclitaxel<p>cyclosporine will increase the level or effect of paclitaxel by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.<span><br><br></span>cyclosporine will increase the level or effect of paclitaxel by  Other (see comment). Use Caution/Monitor. may increase plasma concentrations of OATP substrates</p></li><li>paclitaxel protein bound<p>cyclosporine will increase the level or effect of paclitaxel protein bound by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>palbociclib<p>cyclosporine will increase the level or effect of palbociclib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>palbociclib will increase the level or effect of cyclosporine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. The dose of  sensitive CYP3A substrates with a narrow therapeutic index may need to be reduced if coadministered with palbociclib</p></li><li>paliperidone<p>cyclosporine will increase the level or effect of paliperidone by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>pantoprazole<p>cyclosporine, pantoprazole.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: When used for prolonged periods of time PPIs may cause hypomagnesemia and the risk is further increased when used concomitantly with drugs that also have the same effects.<span><br><br></span>pantoprazole, cyclosporine.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: When used for prolonged periods of time PPIs may cause hypomagnesemia and the risk is further increased when used concomitantly with drugs that also have the same effects.</p></li><li>parecoxib<p>parecoxib increases toxicity of cyclosporine by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis, increasing the risk of nephrotoxicity.</p></li><li>paromomycin<p>cyclosporine will increase the level or effect of paromomycin by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.<span><br><br></span>cyclosporine and paromomycin both increase  nephrotoxicity and/or ototoxicity. Use Caution/Monitor.</p></li><li>pasireotide<p>pasireotide decreases levels of cyclosporine by unspecified interaction mechanism. Use Caution/Monitor. Coadministration may decrease bioavailability of cyclosporine.</p></li><li>pazopanib<p>cyclosporine will increase the level or effect of pazopanib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>peginterferon alfa 2a<p>peginterferon alfa 2a will increase the level or effect of cyclosporine by  affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor.</p></li><li>pentamidine<p>cyclosporine and pentamidine both increase  nephrotoxicity and/or ototoxicity. Use Caution/Monitor.</p></li><li>pentobarbital<p>pentobarbital will decrease the level or effect of cyclosporine by  affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor.<span><br><br></span>pentobarbital will decrease the level or effect of cyclosporine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>peramivir<p>cyclosporine increases levels of peramivir by decreasing renal clearance. Use Caution/Monitor. Caution when peramivir coadministered with nephrotoxic drugs.</p></li><li>perindopril<p>perindopril, cyclosporine. Mechanism: unspecified interaction mechanism. Use Caution/Monitor. Risk of acute renal failure.</p></li><li>phenobarbital<p>phenobarbital will decrease the level or effect of cyclosporine by  affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor.<span><br><br></span>phenobarbital will decrease the level or effect of cyclosporine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>phenobarbital will decrease the level or effect of cyclosporine by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>phenytoin<p>phenytoin will decrease the level or effect of cyclosporine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>phenytoin will decrease the level or effect of cyclosporine by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>pipemidic acid<p>pipemidic acid will increase the level or effect of cyclosporine by  affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor.</p></li><li>piroxicam<p>piroxicam, cyclosporine.
Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely.</p></li><li>polymyxin b<p>cyclosporine and polymyxin b both increase  nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely.</p></li><li>ponatinib<p>ponatinib increases levels of cyclosporine by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>posaconazole<p>posaconazole will increase the level or effect of cyclosporine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>cyclosporine will increase the level or effect of posaconazole by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>potassium citrate<p>cyclosporine and potassium citrate both increase  serum potassium. Use Caution/Monitor.</p></li><li>potassium citrate/citric acid<p>cyclosporine and potassium citrate/citric acid both increase  serum potassium. Use Caution/Monitor.</p></li><li>prednisolone<p>cyclosporine will increase the level or effect of prednisolone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>cyclosporine will increase the level or effect of prednisolone by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>prednisone<p>cyclosporine will increase the level or effect of prednisone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>cyclosporine will increase the level or effect of prednisone by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>primidone<p>primidone will decrease the level or effect of cyclosporine by  affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor.<span><br><br></span>primidone will decrease the level or effect of cyclosporine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>quercetin<p>quercetin will decrease the level or effect of cyclosporine by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>quetiapine<p>cyclosporine will increase the level or effect of quetiapine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>quinapril<p>quinapril, cyclosporine. Mechanism: unspecified interaction mechanism. Use Caution/Monitor. Risk of acute renal failure.</p></li><li>quinidine<p>cyclosporine will increase the level or effect of quinidine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>quinupristin/dalfopristin<p>quinupristin/dalfopristin will increase the level or effect of cyclosporine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>rabeprazole<p>cyclosporine, rabeprazole.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: When used for prolonged periods of time PPIs may cause hypomagnesemia and the risk is further increased when used concomitantly with drugs that also have the same effects.<span><br><br></span>rabeprazole, cyclosporine.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: When used for prolonged periods of time PPIs may cause hypomagnesemia and the risk is further increased when used concomitantly with drugs that also have the same effects.</p></li><li>ramipril<p>ramipril, cyclosporine. Mechanism: unspecified interaction mechanism. Use Caution/Monitor. Risk of acute renal failure.</p></li><li>ranitidine<p>ranitidine will increase the level or effect of cyclosporine by  unknown mechanism. Use Caution/Monitor.</p></li><li>ranolazine<p>ranolazine will increase the level or effect of cyclosporine by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>repaglinide<p>cyclosporine will increase the level or effect of repaglinide by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>cyclosporine increases levels of repaglinide by Other (see comment). Use Caution/Monitor. 
Comment: Repaglinide  is a substrate for active hepatic uptake transporter protein OATP1B1; cyclosporine inhibits this protein and may increase levels of repaglinide; repaglinide may require dose reduction.</p></li><li>reserpine<p>reserpine will decrease the level or effect of cyclosporine by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>ribociclib<p>ribociclib will increase the level or effect of cyclosporine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Caution if ribociclib is coadministered with sensitive CYP3A4 substrates that have a narrow therapeutic index. Dose reduction for sensitive CYP3A4 substrates may be needed.</p></li><li>rifampin<p>rifampin will decrease the level or effect of cyclosporine by  affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor.<span><br><br></span>rifampin will decrease the level or effect of cyclosporine by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>rifapentine<p>rifapentine will decrease the level or effect of cyclosporine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>rifaximin<p>cyclosporine increases levels of rifaximin by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor. Coadministration of cyclosporine with rifaximin resulted in 83-fold and 124-fold increases in rifaximin mean Cmax and AUC in healthy subjects.</p></li><li>rimonabant<p>cyclosporine will increase the level or effect of rimonabant by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>risperidone<p>cyclosporine will increase the level or effect of risperidone by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>ritonavir<p>cyclosporine will increase the level or effect of ritonavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>cyclosporine will increase the level or effect of ritonavir by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>rivaroxaban<p>cyclosporine increases levels of rivaroxaban by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Patients with renal impairment receiving rivaroxaban with drugs that are combined P-gp and weak or moderate CYP3A4 inhibitors may have significant increases in exposure compared with patients with normal renal function and no inhibitor use, since both pathways of rivaroxaban elimination are affected. Since these increases may increase bleeding risk, use rivaroxaban in this situation only if the potential benefit justifies the potential risk.</p></li><li>rolapitant<p>rolapitant will increase the level or effect of cyclosporine by  P-glycoprotein (MDR1) efflux transporter. Modify Therapy/Monitor Closely. Monitor for adverse reactions when unable to avoid coadministration with narrow therapeutic index P-gp substrates.</p></li><li>romidepsin<p>cyclosporine will increase the level or effect of romidepsin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>cyclosporine will increase the level or effect of romidepsin by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>roxithromycin<p>roxithromycin increases levels of cyclosporine by decreasing metabolism. Use Caution/Monitor.</p></li><li>rufinamide<p>rufinamide will decrease the level or effect of cyclosporine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>ruxolitinib<p>cyclosporine will increase the level or effect of ruxolitinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>sacubitril/valsartan<p>cyclosporine will increase the level or effect of sacubitril/valsartan by  Other (see comment). Use Caution/Monitor. The results from an in vitro study with human liver tissue indicate that valsartan is a substrate of the hepatic uptake transporter OATP1B1; coadministration with OATP1B1 inhibitors may increase valsartan systemic exposure</p></li><li>salicylates (non-asa)<p>salicylates (non-asa) increases toxicity of cyclosporine by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis, increasing the risk of nephrotoxicity.</p></li><li>saquinavir<p>cyclosporine will increase the level or effect of saquinavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>cyclosporine will increase the level or effect of saquinavir by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.<span><br><br></span>saquinavir increases levels of cyclosporine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>schisandra<p>schisandra will increase the level or effect of cyclosporine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>secobarbital<p>secobarbital will decrease the level or effect of cyclosporine by  affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor.<span><br><br></span>secobarbital will decrease the level or effect of cyclosporine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>secukinumab<p>secukinumab, cyclosporine. Other (see comment). Use Caution/Monitor. 
Comment: Formation of CYP450 enzymes can be altered by increased levels of certain cytokines during chronic inflammation; thus, secukinumab could normalize the formation of CYP450 enzymes. Upon initiation or discontinuation of secukinumab in patients who are receiving concomitant CYP450 substrates, particularly those with a narrow therapeutic index, consider monitoring for therapeutic effect.</p></li><li>sildenafil<p>cyclosporine will increase the level or effect of sildenafil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>silodosin<p>cyclosporine will increase the level or effect of silodosin by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>siltuximab<p>siltuximab, cyclosporine. Other (see comment). Use Caution/Monitor. 
Comment: CYP450 activity in the liver is down regulated by infection and inflammation stimuli including cytokines (eg, IL-6); inhibition of IL-6 by siltuximab may restore CYP450 enzymatic activity; caution if coadministered with CYP substrates that have a narrow therapeutic index.</p></li><li>simeprevir<p>simeprevir increases levels of cyclosporine by Other (see comment). Use Caution/Monitor. 
Comment: No dose adjustment is required when coadministered; routine monitoring of blood concentrations of cyclosporine is acceptable.</p></li><li>sipuleucel-t<p>cyclosporine decreases effects of sipuleucel-t by pharmacodynamic antagonism. Modify Therapy/Monitor Closely.</p></li><li>sirolimus<p>cyclosporine will increase the level or effect of sirolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Simultaneous coadministration significantly increases sirolimus levels; this is minimized by administering sirolimus 4 hr after cyclosporine <span><br><br></span>cyclosporine will increase the level or effect of sirolimus by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor. Simultaneous coadministration significantly increases sirolimus levels; this is minimized by administering sirolimus 4 hr after cyclosporine<span><br><br></span>cyclosporine and sirolimus both increase  immunosuppressive effects; risk of infection. Use Caution/Monitor.<span><br><br></span>sirolimus increases toxicity of cyclosporine by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Elevations in serum creatinine, hemolytic uremic syndrome, TTP, and microangiopathy were observed when sirolimus used in combination with full-dose cyclosporine; this effect is often reversible with cyclosporine dose reduction.</p></li><li>sitaxentan<p>sitaxentan will increase the level or effect of cyclosporine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>smoking<p>smoking will decrease the level or effect of cyclosporine by  affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor.</p></li><li>sodium bicarbonate<p>sodium bicarbonate decreases levels of cyclosporine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Separate by 2 hours.</p></li><li>sodium citrate/citric acid<p>sodium citrate/citric acid decreases levels of cyclosporine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Separate by 2 hours.</p></li><li>sofosbuvir/velpatasvir<p>sofosbuvir/velpatasvir will increase the level or effect of cyclosporine by  P-glycoprotein (MDR1) efflux transporter. Modify Therapy/Monitor Closely. Velpatasvir inhibits P-gp. Closely monitor P-gp substrates, particularly those with a narrow therapeutic index. Modify dose if needed.<span><br><br></span>sofosbuvir/velpatasvir increases levels of cyclosporine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Velpatasvir inhibits CYP3A4. Caution if coadministered with drugs with narrow therapeutics indexes.</p></li><li>solifenacin<p>cyclosporine will increase the level or effect of solifenacin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>sonidegib<p>cyclosporine will increase the level or effect of sonidegib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Avoid coadministration of sonidegib with moderate CYP3A4 inhibitors. If a moderate CYP3A inhibitor must be used, administer the moderate CYP3A inhibitor for &lt;14 days and monitor closely for adverse reactions, particularly musculoskeletal adverse reactions.</p></li><li>spironolactone<p>spironolactone will increase the level or effect of cyclosporine by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>st john's wort<p>st john's wort will decrease the level or effect of cyclosporine by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>streptomycin<p>cyclosporine will increase the level or effect of streptomycin by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.<span><br><br></span>cyclosporine and streptomycin both increase  nephrotoxicity and/or ototoxicity. Use Caution/Monitor.</p></li><li>streptozocin<p>cyclosporine and streptozocin both increase  nephrotoxicity and/or ototoxicity. Use Caution/Monitor.</p></li><li>sulfasalazine<p>sulfasalazine increases toxicity of cyclosporine by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis, increasing the risk of nephrotoxicity.</p></li><li>sulindac<p>sulindac, cyclosporine.
Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely.</p></li><li>sunitinib<p>cyclosporine will increase the level or effect of sunitinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>suvorexant<p>cyclosporine will increase the level or effect of suvorexant by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Decrease suvorexant starting dose to 5 mg HS if coadministered with moderate CYP3A4 inhibitors</p></li><li>tacrine<p>tacrine will increase the level or effect of cyclosporine by  affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor.</p></li><li>tacrolimus<p>cyclosporine will increase the level or effect of tacrolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>cyclosporine will increase the level or effect of tacrolimus by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>tadalafil<p>cyclosporine will increase the level or effect of tadalafil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>tamoxifen<p>cyclosporine, tamoxifen. affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. CYP3A4 inhibition decreases metabolism of tamoxifen to N-desmethyl tamoxifen (active metabolite with similar biologic activity).</p></li><li>tamsulosin<p>cyclosporine increases levels of tamsulosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Dose reduction may be needed for coadministered drugs that are predominantly metabolized by CYP3A.</p></li><li>teduglutide<p>teduglutide increases levels of cyclosporine by Other (see comment). Use Caution/Monitor. 
Comment: Teduglutide may increase absorption of concomitant PO medications; caution with with drugs requiring titration or those with a narrow therapeutic index; dose adjustment may be necessary.</p></li><li>telaprevir<p>telaprevir increases levels of cyclosporine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Significant dose reductions and prolongation of the dosing interval of the immunosuppressant to achieve the desired blood levels should be anticipated. Close monitoring of the immunosuppressant blood levels, and frequent assessments of renal function and immunosuppressant-related side effects are recommended when co-administered with telaprevir. .</p></li><li>telotristat ethyl<p>telotristat ethyl will decrease the level or effect of cyclosporine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Telotristat ethyl induces CYP3A4 and may reduce systemic exposure of sensitive CYP3A4 substrates. Monitor for suboptimal efficacy and consider increasing the dose of the CYP3A4 substrate.</p></li><li>temsirolimus<p>cyclosporine will increase the level or effect of temsirolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>teniposide<p>cyclosporine will increase the level or effect of teniposide by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>tenofovir df<p>cyclosporine and tenofovir df both increase  nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely.</p></li><li>tesamorelin<p>tesamorelin will decrease the level or effect of cyclosporine by  altering metabolism. Modify Therapy/Monitor Closely. Monitor levels</p></li><li>theophylline<p>cyclosporine will increase the level or effect of theophylline by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>tipranavir<p>cyclosporine will increase the level or effect of tipranavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>tipranavir, cyclosporine. Other (see comment). Use Caution/Monitor. 
Comment: Cyclosporine levels may incr or decr, due to contradictory effects of tipranavir on hepatic CYP3A4 and P glycoprotein.</p></li><li>tobacco use<p>tobacco use will decrease the level or effect of cyclosporine by  affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor.</p></li><li>tobramycin<p>cyclosporine will increase the level or effect of tobramycin by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.<span><br><br></span>cyclosporine and tobramycin both increase  nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely.</p></li><li>tofacitinib<p>cyclosporine increases levels of tofacitinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. No specific dose adjustment recommended when tofacitinib coadministered with moderate CYP3A4 inhibitors; decrease tofacitinib dose if coadministered with both moderate CYP3A4 and potent CYP2C19 inhibitors.</p></li><li>tolfenamic acid<p>tolfenamic acid increases toxicity of cyclosporine by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis, increasing the risk of nephrotoxicity.</p></li><li>tolmetin<p>tolmetin, cyclosporine.
Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely.</p></li><li>tolterodine<p>cyclosporine will increase the level or effect of tolterodine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>tolvaptan<p>cyclosporine will increase the level or effect of tolvaptan by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.<span><br><br></span>tolvaptan will increase the level or effect of cyclosporine by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>topiramate<p>topiramate will decrease the level or effect of cyclosporine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>trabectedin<p>cyclosporine will increase the level or effect of trabectedin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>trandolapril<p>trandolapril, cyclosporine. Mechanism: unspecified interaction mechanism. Use Caution/Monitor. Risk of acute renal failure.</p></li><li>trazodone<p>cyclosporine will increase the level or effect of trazodone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>trazodone will decrease the level or effect of cyclosporine by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>triamcinolone<p>cyclosporine will increase the level or effect of triamcinolone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>cyclosporine will increase the level or effect of triamcinolone by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>triazolam<p>cyclosporine will increase the level or effect of triazolam by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>trimethoprim<p>trimethoprim and cyclosporine both increase  serum potassium. Use Caution/Monitor. Trimethoprim decreases urinary potassium excretion. May cause hyperkalemia, particularly with high doses, renal insufficiency, or when combined with other drugs that cause hyperkalemia.</p></li><li>troglitazone<p>troglitazone will decrease the level or effect of cyclosporine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>cyclosporine will increase the level or effect of troglitazone by  Other (see comment). Use Caution/Monitor. may increase plasma concentrations of OATP substrates</p></li><li>troleandomycin<p>troleandomycin will increase the level or effect of cyclosporine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>unoprostone ophthalmic<p>cyclosporine will increase the level or effect of unoprostone ophthalmic by  Other (see comment). Use Caution/Monitor. may increase plasma concentrations of OATP substrates</p></li><li>valsartan<p>cyclosporine will increase the level or effect of valsartan by  Other (see comment). Use Caution/Monitor. The results from an in vitro study with human liver tissue indicate that valsartan is a substrate of the hepatic uptake transporter OATP1B1; coadministration with OATP1B1 inhibitors may increase valsartan systemic exposure</p></li><li>vancomycin<p>cyclosporine and vancomycin both increase  nephrotoxicity and/or ototoxicity. Use Caution/Monitor.</p></li><li>vardenafil<p>cyclosporine will increase the level or effect of vardenafil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>vemurafenib<p>cyclosporine increases levels of vemurafenib by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.<span><br><br></span>vemurafenib increases levels of cyclosporine by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>verapamil<p>verapamil will increase the level or effect of cyclosporine by  affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor.<span><br><br></span>cyclosporine will increase the level or effect of verapamil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>verapamil will increase the level or effect of cyclosporine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>verapamil will increase the level or effect of cyclosporine by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>vinblastine<p>cyclosporine will increase the level or effect of vinblastine by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>vincristine<p>cyclosporine will increase the level or effect of vincristine by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>vincristine liposomal<p>cyclosporine will increase the level or effect of vincristine liposomal by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>vismodegib<p>cyclosporine will increase the level or effect of vismodegib by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor. Vismodegib is a substrate of efflux transporter P-glycoprotein (P-gp); coadministration with P-gp inhibitors increase vismodegib systemic exposure</p></li><li>voriconazole<p>voriconazole will increase the level or effect of cyclosporine by  altering metabolism. Modify Therapy/Monitor Closely. voriconazole may inrease blood levels of cyclosporine; monitor closely and adjust cyclosporine therapy as needed</p></li><li>warfarin<p>cyclosporine will increase the level or effect of warfarin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>wine red<p>wine red decreases levels of cyclosporine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Neoral may be less affected than Sandimmune.</p></li><li>zafirlukast<p>zafirlukast will increase the level or effect of cyclosporine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>zileuton<p>zileuton will increase the level or effect of cyclosporine by  affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor.</p></li>